Crescent Grove Advisors LLC Has $819,000 Holdings in Pfizer Inc. (NYSE:PFE)

Crescent Grove Advisors LLC decreased its holdings in shares of Pfizer Inc. (NYSE:PFE – Get Rating) by 18.6% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 18,717 shares of the biopharmaceutical company’s stock after selling 4,284 shares during the quarter. Crescent Grove Advisors LLC’s holdings in Pfizer were worth $819,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in PFE. RB Capital Management LLC boosted its holdings in Pfizer by 6.7% during the first quarter. RB Capital Management LLC now owns 5,446 shares of the biopharmaceutical company’s stock worth $282,000 after purchasing an additional 341 shares during the last quarter. Ironwood Wealth Management LLC. lifted its stake in Pfizer by 1.1% in the first quarter. Ironwood Wealth Management LLC. now owns 36,081 shares of the biopharmaceutical company’s stock valued at $1,868,000 after acquiring an additional 400 shares during the last quarter. United Bank lifted its stake in Pfizer by 0.6% in the first quarter. United Bank now owns 46,671 shares of the biopharmaceutical company’s stock valued at $2,416,000 after acquiring an additional 290 shares during the last quarter. Ergoteles LLC lifted its stake in Pfizer by 136.3% in the first quarter. Ergoteles LLC now owns 36,766 shares of the biopharmaceutical company’s stock valued at $1,903,000 after acquiring an additional 21,209 shares during the last quarter. Finally, Mackenzie Financial Corp lifted its stake in Pfizer by 6.4% in the first quarter. Mackenzie Financial Corp now owns 1,337,418 shares of the biopharmaceutical company’s stock valued at $69,238,000 after acquiring an additional 79,887 shares during the last quarter. Institutional investors and hedge funds own 67.62% of the company’s stock.

Pfizer Price Performance

NYSE:PFE opened at $43.70 on Thursday. Pfizer Inc. has a 52 week low of $41.44 and a 52 week high of $56.32. The firm has a market cap of $245.30 billion, a price-to-earnings ratio of 8.02, a P/E/G ratio of 1.46 and a beta of 0.63. The firm’s 50-day simple moving average is $49.26 and its 200 day simple moving average is $47.78. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.37 and a current ratio of 1.59.

Pfizer (NYSE:PFE – Get Rating) last released its quarterly earnings results on Tuesday, January 31st. The biopharmaceutical company reported $1.14 EPS for the quarter, topping analysts’ consensus estimates of $1.03 by $0.11. Pfizer had a net margin of 31.27% and a return on equity of 43.02%. The business had revenue of $24.30 billion for the quarter, compared to analyst estimates of $24.40 billion. During the same period last year, the firm earned $1.08 earnings per share. Pfizer’s revenue for the quarter was up 1.9% compared to the same quarter last year. As a group, sell-side analysts predict that Pfizer Inc. will post 3.35 earnings per share for the current year.

Pfizer Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 3rd. Shareholders of record on Friday, January 27th will be issued a $0.41 dividend. This is a positive change from Pfizer’s previous quarterly dividend of $0.40. This represents a $1.64 annualized dividend and a yield of 3.75%. The ex-dividend date of this dividend is Thursday, January 26th. Pfizer’s dividend payout ratio (DPR) is currently 29.93%.

Analyst Upgrades and Downgrades

A number of analysts have commented on the stock. Credit Suisse Group cut their price target on shares of Pfizer from $54.00 to $50.00 and set an “outperform” rating for the company in a research note on Wednesday. UBS Group set a $45.00 price target on shares of Pfizer in a research note on Wednesday. Barclays cut their price target on shares of Pfizer from $49.00 to $44.00 and set an “equal weight” rating for the company in a research note on Wednesday. StockNews.com cut shares of Pfizer from a “strong-buy” rating to a “buy” rating in a research note on Wednesday. Finally, Atlantic Securities cut their target price on shares of Pfizer from $50.00 to $46.00 and set a “neutral” rating for the company in a research note on Wednesday. Eight equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $52.13.

Pfizer Company Profile

(Get Rating)

Pfizer Inc is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.